Showing 4961-4970 of 5771 results for "".
- Optos Unveils Silverstone Combined Ultra-Widefield Retinal Imaging Device and UWF-Guided Swept Source OCThttps://modernod.com/news/optos-unveils-silverstone-combined-ultra-widefield-retinal-imaging-device-and-uwf-guided-swept-source-oct/2476998/Optos has announced the launch of Silverstone at the American Academy of Ophthalmology in San Francisco. Silverstone is the first-of-its-kind, combining world-leading ultra-widefield retinal imaging with integrated, image-guided, swept source OCT. Silverstone produces a 200° single capture
- Norlase Enters Ophthalmic Market With Launch of LEAF Ultra-Compact Green Laser Photocoagulatorhttps://modernod.com/news/norlase-enters-ophthalmic-market-with-launch-of-leaf-ultra-compact-green-laser-photocoagulator/2476999/Norlase announced the FDA 510(k) clearance and immediate commercial launch of LEAF, the company’s flagship laser product for the treatment of retina and glaucoma disease. LEAF allows ophthalmologists to perform laser therapy in almost any exam room, with minimal set-up time and physical space req
- Zeiss Showcases New Digital Technologies and Diagnostics at AAOhttps://modernod.com/news/zeiss-showcases-new-digital-technologies-and-diagnostics-at-aao/2477001/At the American Academy of Ophthalmology (AAO) annual meeting in San Francisco, Zeiss is presenting the latest in
- Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Wet AMDhttps://modernod.com/news/allergan-and-molecular-partners-present-late-breaking-data-from-phase-3-studies-of-investigational-abicipar-pegol-in-wet-amd/2476996/Allergan and Molecular Partners announced 2-year data from the CEDAR and SEQUOIA clinical studies of investigational Abicipar in patients with wet age-related macular degeneration (AMD). In the second year of these studies, four injections of Abicipar resulted in the maintenance of visual gains c
- Glaukos Achieves Pipeline Milestone with Completion of Patient Enrollment in US IDE Trial for iStent infinitehttps://modernod.com/news/glaukos-achieves-pipeline-milestone-with-completion-of-patient-enrollment-in-us-ide-trial-for-istent-infinite/2476990/Glaukos announced the completion of patient enrollment in its FDA Investigational Device Exemption (IDE) trial for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is designed for use in a standalone procedure to reduce elevated IOP in refractory glaucoma patients. I
- Phase 3 Study Shows Teprotumumab Significantly Reduced Double Vision for People with Active Thyroid Eye Diseasehttps://modernod.com/news/new-data-from-teprotumumab-phase-3-study-shows-significantly-reduced-double-vision-for-people-with-active-thyroid-eye-disease/2476988/Horizon Therapeutics announced new data from the phase 3 OPTIC confirmatory clinical trial showing that teprotumumab provided significant benefit on several effects of active thyroid eye disease (TED) compared with placebo, including diplopia (double vision), quality of life (QoL) and clinical ac
- Intelligent Retinal Imaging Systems (IRIS) Partners with Remidio Innovative Solutions to Provide Early Detection Systems for Diabetic Eye Diseasehttps://modernod.com/news/intelligent-retinal-imaging-systems-iris-partners-with-remidio-innovative-solutions-to-provide-early-detection-systems-for-diabetic-eye-disease/2476989/Intelligent Retinal Imaging Systems (IRIS) announced a partnership with Remidio Innovative Solutions to bring their smartphone based non-mydriatic fundus camera to the U.S. market. Coupling the IRIS software and services program with an affordable and high-quality handheld camera will allow more
- Eyevensys Presents Initial Data from Phase 1/2 Trial of Non-Viral Gene Therapy for Ocular Diseaseshttps://modernod.com/news/eyevensys-presents-initial-data-from-phase-1-2-trial-of-non-viral-gene-therapy-for-ocular-diseases/2476987/Eyevensys this week presented results from part 1 of its phase 1/2 study for noninfectious uveitis (NIU) at the Ophthalmology Innovation Summit’s (OIS) 11th Annual OIS@AAO conference on October 10, 2019 in San Francisco. Ronald R. Buggage, MD, Chief Medical Officer of Eyevensys, discussed the nov
- eSight 3 Approved on the US Department of Veterans Affairs (VA) Federal Supply Schedulehttps://modernod.com/news/esight-3-approved-on-the-us-department-of-veterans-affairs-va-federal-supply-schedule/2476985/eSight announced the approval of eSight 3–advanced sight-enhancing glasses for those living with visual impairments–on the United States Department of Veterans Affairs (VA) Federal Supply Schedule (FSS). The registration allows eSight to be included on the FSS through December 2023.<
- World’s Leading Eye Physicians and Surgeons Gather in San Francisco to Inspire the Future of Eye Carehttps://modernod.com/news/worlds-leading-eye-physicians-and-surgeons-gather-in-san-francisco-to-inspire-the-future-of-eye-care/2476986/More than 25,000 are expected to attend the American Academy of Ophthalmology’s 123rd annual meeting, AAO 2019, from Oct. 12-15 at the Moscone Center in San Francisco. The 4-day meeting offers opportunities to hear from the greatest minds in medical and surgical eye care discuss the la